Preferred Label : irinotecan sucrosofate;

MeSH note : combination of irinotecan and sucrosofate;

UNII : OL741S3N8B;

Details


Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-pegylated-liposomal
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Metastatic Pancreatic Adenocarcinoma
neoplasm metastasis
Pegylated Liposomal Irinotecan
Pegylated Liposomal Irinotecan
liposomes
pancreatic neoplasms
irinotecan sucrosofate
irinotecan sucrosofate
antineoplastic agents
antineoplastic agents
pregnancy
breast feeding
drug interactions
antineoplastic combined chemotherapy protocols
fluorouracil
leucovorin
Fluorouracil/Liposomal Irinotecan/Leucovorin Regimen
orphan drug production
infusions, intravenous
topoisomerase I inhibitors
topoisomerase I inhibitors
aged
DNA topoisomerases, type I
survival analysis
drug evaluation, preclinical
drug approval
europe
Irinotecan hydrochloride trihydrate (substance)
adult
adenocarcinoma
camptothecin
camptothecin
drug combinations
sucrose
sucrose
camptothecin
drug combinations
sucrose

---
Nous contacter.
19/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.